NCT05075993 2025-12-26
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
Clinical Trials
11 trialsNCT01746238 2025-12-19
Bevacizumab/Doxorubicin/Radiation for Sarcoma
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT01552434 2025-10-14
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT01492673 2019-10-29
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01661283 2019-03-06
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT01106872 2018-08-10
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
University of Iowa
Phase 1 Completed
NCT00356031 2017-05-19
Bevacizumab and Radiation Therapy for Sarcomas
Massachusetts General Hospital
Phase 2 Completed
NCT00887809 2016-01-25
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00276055 2015-06-19
Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma
New Mexico Cancer Research Alliance
Phase 1 Completed
NCT00755261 2015-05-08
Phase II Study of Doxorubicin and Avastin® in Sarcoma.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated